Advertisement

FDA OKs Schwarz's Neupro for Parkinson's

MONHEIM, Germany, May 10 (UPI) -- Schwarz said Thursday the U.S. Food and Drug Administration approved Neupro for the treatment of early-stage Parkinson's disease.

Neupro consists of a patch applied once daily that delivers the dopamine agonist rotigotine. The product was approved in Europe last year.

Advertisement

"Following approval and launch within Europe, Neupro will now be available for patients in the (United States)," said Iris Loew-Friedrich, Schwarz's chief scientific officer.

Neupro said it also plans to seek an indication for Neupro for the treatment of advanced Parkinson's.

"We intend to submit a supplemental new drug application for the treatment of advanced Parkinson's disease to the FDA by the end of 2007," Loew-Friedrich said.

Latest Headlines